BioAlliance Pharma SA (Euronext Paris – BIO — FR0010095596), an innovative Company dedicated to orphan oncology products and specialty products, today launches a capital increase with maintenance of preferential subscription rights for an amount of € 7.94 million [The amount may be increased to € 8.74 million resulting from the full exercise of the extension clause].
This capital increase will enable BioAlliance Pharma:
“We are pursuing our value creation strategy based on the development of our therapeutic innovations in severe and rare diseases in oncology where the medical need is strong and which represent very high market potentials”, declares Judith Greciet, CEO of BioAlliance Pharma. “Thanks to this financing, we would intend on accelerating the development of our two most advanced programs to enable potential growth for the Company.”
Main features of the operation